Evidence map›Paper›PMID 36006995›Full record

ArticleCancer research2022

Notch Signaling Promotes Mature T-Cell Lymphomagenesis.

Xin Gao, Chenguang Wang, Suhaib Abdelrahman, Nermin Kady, Carlos Murga-Zamalloa, Peter Gann, Maria Sverdlov, Ashley Wolfe, Avery Polk, Noah Brown and 10 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 3 countries.

Xin GaoDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0001-8622-1522
Chenguang WangDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-9082-2117
Suhaib AbdelrahmanDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-0483-0074
Nermin KadyDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0001-8670-8752
Carlos Murga-ZamalloaDepartment of Pathology, University of Illinois Chicago, Chicago, Illinois.ORCID 0000-0002-2238-5066
Peter GannDepartment of Pathology, University of Illinois Chicago, Chicago, Illinois.ORCID 0000-0002-9439-2900
Maria SverdlovDepartment of Pathology, University of Illinois Chicago, Chicago, Illinois.ORCID 0000-0002-1893-865X
Ashley WolfeDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-0340-2788
Avery PolkDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-3213-185X
Noah BrownDepartment of Pathology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0001-9151-5912
Nathanael G BaileyDivision of Hematopathology, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-6747-680X
Kedar InamdarDepartment of Pathology, Henry Ford Hospital, Detroit, Michigan.ORCID 0000-0002-0428-8748
Sandro Casavilca-ZambranoDepartment of Pathology, Instituto Nacional de Enfermedades Neoplasicas (INEN), Lima, Peru.ORCID 0000-0001-8406-739X
Jaime MontesDepartment of Pathology, Instituto Nacional de Enfermedades Neoplasicas (INEN), Lima, Peru.ORCID 0000-0003-3980-4199
Carlos BarrionuevoDepartment of Pathology, Instituto Nacional de Enfermedades Neoplasicas (INEN), Lima, Peru.ORCID 0000-0003-2474-914X
Luis TaxaDepartment of Pathology, Instituto Nacional de Enfermedades Neoplasicas (INEN), Lima, Peru.ORCID 0000-0002-0914-9149
John ReneauDepartment of Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0001-6838-2410
Christian W SiebelDepartment of Discovery Oncology, Genentech, Inc., South San Francisco, California.ORCID 0000-0003-4333-3756
Ivan MaillardDepartment of Medicine, Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0003-1312-6748
Ryan A WilcoxDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-6420-0760
University of Michigan · USInstituto Nacional de Enfermedades Neoplásicas · PEUniversity of Illinois Chicago · USDiscovery Centre · CAHenry Ford Hospital · USThe Ohio State University · USUniversity of Pennsylvania · USUniversity of Pittsburgh · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Notch Signaling in AlloimmunityR01AI091627 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI PEAR, WARREN S · 2011 to 2025
$6.0M
THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESISR37CA233476 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WILCOX, RYAN A · 2019 to 2025
$2.2M
Notch and GATA-3 as novel therapeutic targets in T-cell lymphomasR01CA236722 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WILCOX, RYAN A · 2020 to 2024
$1.8M
NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA236722NCI NIH HHS R37 CA233476NIAID NIH HHS R01 AI091627
6 · The paper itself

Abstract

Peripheral T-cell lymphomas (PTCL) are agressive lymphomas that develop from mature T cells. The most common PTCLs are genetically, molecularly, and clinically diverse and are generally associated with dismal outcomes. While Notch signaling plays a critically important role in both the development of immature T cells and their malignant transformation, its role in PTCL is poorly understood, despite the increasingly appreciated function of Notch in regulating the proliferation and differentiation of mature T cells. Here, we demonstrate that Notch receptors and their Delta-like family ligands (DLL1/DLL4) play a pathogenic role in PTCL. Notch1 activation was observed in common PTCL subtypes, including PTCL-not otherwise specified (NOS). In a large cohort of PTCL-NOS biopsies, Notch1 activation was significantly associated with surrogate markers of proliferation. Complementary genetically engineered mouse models and spontaneous PTCL models were used to functionally examine the role of Notch signaling, and Notch1/Notch2 blockade and pan-Notch blockade using dominant-negative MAML significantly impaired the proliferation of malignant T cells and PTCL progression in these models. Treatment with DLL1/DLL4 blocking antibodies established that Notch signaling is ligand-dependent. Together, these findings reveal a role for ligand-dependent Notch signaling in driving peripheral T-cell lymphomagenesis. SIGNIFICANCE: This work demonstrates that ligand-dependent Notch activation promotes the growth and proliferation of mature T-cell lymphomas, providing new therapeutic strategies for this group of aggressive lymphomas.

Indexed as

Signal TransductionT-LymphocytesAnimalsAntibodies, BlockingLigandsMiceReceptor, Notch1Receptors, NotchAntibodies, BlockingLigandsReceptor, Notch1Receptors, Notch

Identifiers

PMID36006995
PMCPMC9588752
OpenAlexW4293101897

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.